Pompili Luca, Porru Manuela, Caruso Carla, Biroccio Annamaria, Leonetti Carlo
UOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, Traslational Research Area, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, 00144, Italy.
University of Tuscia, Viterbo, Italy.
J Exp Clin Cancer Res. 2016 Dec 5;35(1):189. doi: 10.1186/s13046-016-0462-4.
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
确定合适的临床前癌症模型仍然是提高药物开发效率的一项重大挑战。提高患者治疗效果的一个潜在策略可能是，在将手术切除的肿瘤直接植入小鼠体内获得的患者来源异种移植瘤（PDX）中进行临床前研究时选择“正确”的治疗方法。这些模型保持了形态学上的相似性，并概括了原始肿瘤的分子特征，因此是评估抗癌药物反应的有用工具。在本综述中，我们将介绍PDX作为预测临床结果的可靠策略的最新应用。还将讨论其主要优点和局限性。
